For instance, sunvozertinib has demonstrated response rates ~60 % in patients with EGFR exon 20 insertion-mutated NSCLC, a population where resistance to first- and second-generation EGFR inhibitors is consistently being described (Xie et al., 2025[139]). This evidence concerns the gene EGFR and non-small cell lung carcinoma.